Idraparinux versus Standard Therapy for Venous Thromboembolic Disease | Zendy

Harry R. Büller | Zendy; Ander Cohen | Zendy; Bruce L. Davidson | Zendy; Hervé Decousus | Zendy; Alexander Gallus | Zendy; Michael Gent | Zendy; G Pillion | Zendy; Franco Piovella | Zendy; Martin H. Prins | Zendy; Gary E. Raskob | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Idraparinux versus Standard Therapy for Venous Thromboembolic Disease

Author(s) -

Harry R. Büller,

Ander Cohen,

Bruce L. Davidson,

Hervé Decousus,

Alexander Gallus,

Michael Gent,

G Pillion,

Franco Piovella,

Martin H. Prins,

Gary E. Raskob

Publication year - 2007

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa064247

Subject(s) - medicine , pulmonary embolism , deep vein , odds ratio , venous thrombosis , vitamin k antagonist , hazard ratio , surgery , low molecular weight heparin , anesthesia , confidence interval , heparin , thrombosis , warfarin , atrial fibrillation

Venous thromboembolism is treated with unfractionated heparin or low-molecular-weight heparin, followed by a vitamin K antagonist. We investigated the potential use of idraparinux, a long-acting inhibitor of activated factor X, as a substitute for standard therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research